Updated Jan 16, 2018 04:00 PM ET
After-Market: $62.09 +0.02 (0.03%) 4:32 PM ET
C Value | F Growth | D Momentum | F VGM
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.
The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.
Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. Merck also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Merck & Company, Inc.
2000 GALLOPING HILL ROAD
KENILWORTH, NJ 07033
|Industry||Large Cap Pharmaceuticals|
|Fiscal Year End||December|
|Last Reported Quarter||12/31/2017|
|Next EPS Date||2/2/2018|
|Current Quarter EPS Consensus Estimate||0.94|
|Current Year EPS Consensus Estimate||3.94|
|Estimated Long-Term EPS Growth Rate||4.90|
|Next EPS Report Date||2/2/2018|
Price and Volume Information
|52 Week High||66.80|
|52 Week Low||53.63|
|20 Day Moving Average||8,761,443.00|
|Target Price Consensus||63.83|
|Shares Outstanding (millions)||2,724.44|
|Market Capitalization (millions)||159,815.47|
|Last Split Date||2/17/1999|
|Change in Payout Ratio||-0.01|
|Last Dividend Payout / Amount||12/14/2017 / $0.48|
|Trailing 12 Months||15.08|
|vs. Previous Year||3.74%|
|vs. Previous Quarter||9.90%|
|vs. Previous Year||-2.00%|
|vs. Previous Quarter||3.98%|
|Price / Sales||4.02|